Background: Resistance to tyrosine kinase inhibitors (TKIs) remains a challenge in management of patients with chronic myeloid leukemia (CML). A better understanding of the BCR-ABL signalling network may lead to better therapy.
Findings
Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy with a hallmark cytogenetic abnormality, i.e., the BCR-ABL fusion oncogene, resulting from the reciprocal translocation of chromosomes 9 and 22 [also known as Philadelphia (Ph) chromosome] [1] . CML is the best and most successful disease model for tyrosine kinase inhibitor (TKI) therapy [2, 3] . Unfortunately, acquired resistance can develop during the course of treatment. Effective therapies that can overcome resistance still remain a challenge for the clinical management of CML [2, 4] . The mechanism of BCR-ABL induced transformation and signaling transduction networks have been intensively characterized over the decades [5] [6] [7] . However, new discoveries related to the BCR-ABL signaling pathway and mechanisms of TKI resistance continues to emerge, leading to a better understanding of disease progression and development of novel therapy [8] [9] [10] .
Protein-tyrosine phosphatase of regenerating liver 3 (PRL-3, encoded by protein tyrosine phosphatase type IVA 3, PTP4A3) belongs to class I cysteine-based protein tyrosine phosphatases (PTPs) with dual-specificity [11] [12] [13] . PRL-3 has been identified as a critical player in cancer cell metastasis, invasion, migration, and tumor angiogenesis [11, [14] [15] [16] . The association between elevated PRL-3 and the development of various human cancers has been validated in a wide range of solid tumors [11, 14, 15] and multiple myeloma [17] .
We recently discovered that poly(rC) binding protein 1 (PCPB1, also known as heterogenous nuclear ribonucleoprotein E1, hnRNP-E1) inhibited PRL-3 protein through binding 5'-UTR (untranslated region) of PRL-3 mRNA [18] and showed that PRL-3, acting as a downstream target of the internal tandem duplication (ITD) of fms-like tyrosine kinase (FLT3) signaling, was implicated in FLT3 inhibitor therapy in acute myeloid leukemia (AML) [19] . Furthermore, PRL-3 also has been demonstrated as an independent prognostic parameter for poor overall survival (OS) and event-free survival (EFS) in AML [20] . Importantly, targeting intracellular PRL-3 protein suppressed cancer growth [21] . In the present study, we hypothesize that PRL-3 might be involved in leukemogenesis of human CML.
Overexprsesion of PRL-3 in CML cell lines and primary patient samples Figure 1B ) [19] . Altogether, our data obtained from Western blot analysis of CML cell lines and primary CML samples, as well as the analysis of a publicly available gene expression dataset demonstrated over-expression of PRL-3 in CML.
Imatinib suppressed PRL-3 through inhibition of STAT pathway
Imatinib blocks the binding of ATP to the BCR-ABL tyrosine kinase [22, 23] , and is currently used as the firstline treatment for CML [2, 4] . To establish a connection between BCR-ABL signalling and PRL-3 expression, we treated human CML cell lines, K562 and KCL-22 cells with Imatinib and assessed the expression of PRL-3. Western blot analysis demonstrated that Imatinib dosedependently decreased p-CrkL (a surrogate marker of BCR-ABL kinase activity), p-STAT3, p-STAT5, as well as PRL-3 ( Figure 2A ). Consistent with the effective inhibition of oncogenic BCR-ABL signalling, cleaved-PARP, a hallmark of apoptosis was increased as a response to the Imatinib treatment ( Figure 2A ). We next tested whether Imatinib could induce PRL-3 protein down-regulation in BaF3 murine hematopoietic cells engineered to express either wild-type, or the Imatinib resistant T315I mutant P210 BCR-ABL. As expected, the expression of p-CrkL, p-STAT3 and PRL-3 was down-regulated in a dosedependent manner in the imatinib sensitive P210 WT cells. In contrast, BCR-ABL activity in P210 T315I cells was resistant to Imatinib even at high doses (10 μM) as indicated by no change in p-CrkL. In this resistant cell line, PRL-3 was not downregulated but rather its level increased at higher doses of Imatinib ( Figure 2B ). Surprisingly, p-STAT5 expression was almost completely abolished in both P210 WT and p210 T315I cells upon exposure to Imatinib ( Figure 2B ). On the other hand, the down-regulation of PRL-3 correlated with the inhibition of STAT3. Consistent with inhibition of BCR-ABL, increased PARP cleavage fragment was observed in cells sensitive to Imatinib (K652, P210 WT), but not in resistant cells (P210 T315I) ( Figure 2B ). In addition to the STAT pathways, PI3K/AKT and MAPK/ERK signalling pathways were also downstream of BCR-ABL signalling and may contribute to the transformation of CML cells [7] . However, inhibition of these two pathways did not correlate with the down-regulation of PRL-3 protein in the P210 and K562 cells (Additional file 2). Taken together, these data suggest PRL-3 is downstream of BCR-ABL mainly through the STAT pathway in CML.
Silencing BCR-ABL fusion gene or STAT3 decreased PRL-3 expression
To further confirm that the downregulation of PRL-3 is not due to off-target effect of Imatinib, we used small interfering RNA (siRNA) to specifically knock down the BCR-ABL fusion gene as reported by Scherr et al [24] . qRT-PCR analysis confirmed the expression of PRL-3 gene was decreased approximate 80% in b3a2_1 siRNA transfected K562 cells, in parallel with reduction of BCR-ABL fusion genes ( Figure 3A) confirming that PRL-3 is downstream of BCR-ABL signalling. To assess the specific role of STAT3 in upstream regulation of PRL-3, we decreased STAT3 mRNA by using siRNA in a Nucelofection device. qRT-PCR showed that the expression of PRL-3 was reduced in STAT3 siRNA expressing K562 cells compared with the control (NC) siRNA expressing K562 cells ( Figure 3B ). These results support the BCR-ABL and STAT3 are specific upstream regulators of PRL-3 signalling.
PRL-3 is involved in CML proliferation, selfrenewal, tumorigenic capacity and drug response
To assess the functional effect of PRL-3 in CML, we knocked down PRL-3 using short-hairpin RNA (shRNA). RT-PCR analysis showed that shRNA-PRL-3 transduced K562 cells (K562-shP) demonstrated significantly reduced PRL-3 mRNA levels as compared to shRNA-scramble control transduced cells (K562-shC) (Figure 4Ai ). K562-shP cells proliferated as much as 2-fold slower than K562-shC at day 8 (p < 0.001) (Figure 4Aii ). K562-shP cells also showed significantly impaired colony generating capacity, an indicator of self-renewal capacity, by 3-fold compared to K562-shC (p < 0.001) (Figure 3Aiii ). We next evaluated the oncogenic role of PRL-3 in CML in vivo. Three million of K562-shC and K562-shP cells were subcutaneously inoculated into the right and left side of NOD/SCID mice, respectively (3 mice total). After 3 weeks, only K562-shC cells developed tumors at average size 800 mm 3 ( Figure 4Aiv , right side of the animals, indicated by black circles) and average tumor weight was 0.967 ± 0.21 g (Figure 4Av ). These results indicate a critical role for PRL-3 in CML cell expansion, and self-renewal in vitro and in vivo. To examine if PRL-3 could be a potential therapeutic target downstream of BCR-ABL especially in TKI resistant cells with BCR-ABL mutations, we utilized RNAi to knock down PRL-3 expression in P210 T315I cells. Downregulation of mouse PRL-3 (mPRL-3) was confirmed by RT-PCR ( Figure 4B , left panel) and qRT-PCR ( Figure 4B, middle panel) . Indeed, while Imatinib had no effect on P210 T315I cells, mPRL-3 silencing led to significant cell death in these cells ( Figure 4B, right panel) .
In summary, the present study demonstrates that PRL-3 is upregulated in human CML cell lines, BCR-ABL transformed cell lines and primary CML patient samples. Interestingly, in a previous study, high expression of PRL-3 has been associated with aggressive phenotype of BCR-ABL positive acute lymphoblastic leukemia (ALL) [25] . This finding, together with our results highlight that PRL-3 is a novel downstream target of the BCR-ABL signalling pathway, and may be a novel mediator of BCR-ABL oncogenic functions such as cell survival and self-renewal. Suppression of PRL-3 could provide potential opportunity for further improving anti-CML therapy, especially in tumors with Imatinib or TKI resistant BCR-ABL mutants. 
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